Is CASI Pharmaceuticals Inc (CASI) a Good Buy in the Biotechnology Industry?

CASI Pharmaceuticals Inc (CASI) is around the top of the Biotechnology industry according to InvestorsObserver. CASI received an overall rating of 56, which means that it scores higher than 56 percent of all stocks. CASI Pharmaceuticals Inc also achieved a score of 74 in the Biotechnology industry, putting it above 74 percent of Biotechnology stocks. Biotechnology is ranked 70 out of the 148 industries.

CASI has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on CASI!

See Full CASI Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With CASI Pharmaceuticals Inc Stock Today?

CASI Pharmaceuticals Inc (CASI) stock has gained 1.72% while the S&P 500 has fallen -0.69% as of 9:50 AM on Thursday, Oct 5. CASI has risen $0.05 from the previous closing price of $2.62 on volume of 10,750 shares. Over the past year the S&P 500 has gained 11.93% while CASI has fallen -2.21%. CASI lost -$3.04 per share the over the last 12 months. Click Here to get the full Stock Report for CASI Pharmaceuticals Inc stock.